camptothecin has been researched along with bafilomycin a1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furukawa, T; Ishikawa, T; Morishima, Y; Nakagawa, H; Osawa, Y; Tamura, A; Wakabayashi, K | 1 |
| Abe, M; Harada, M; Itou, M; Kawaguchi, T; Koga, H; Kuromatsu, R; Okuda, K; Sakata, M; Sata, M; Sumie, S; Taniguchi, E; Ueno, T; Yamagishi, S | 1 |
2 other study(ies) available for camptothecin and bafilomycin a1
| Article | Year |
|---|---|
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Immunoblotting; Irinotecan; Leupeptins; Lysosomes; Macrolides; Microscopy, Fluorescence; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; RNA, Messenger; Time Factors; Ubiquitin | 2009 |
Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells.
Topics: Apoptosis; bcl-X Protein; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cyclophilins; Densitometry; Eye Proteins; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Leupeptins; Liver; Liver Neoplasms; Lysosomes; Macrolides; Nerve Growth Factors; Protein Processing, Post-Translational; Recombinant Proteins; RNA, Messenger; Serpins | 2010 |